Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analyst: OMB Review Of MCIT Breakthrough Rule Hints It May Not Be Implemented Anytime Soon

Executive Summary

Health analyst John Leppard says the US CMS is likely to significantly delay implementation or even take the Medicare Coverage for Innovative Technology reg back to the drawing board.

You may also be interested in...



MCIT Rule Likely Too Broken For CMS To Implement In December, Analyst Predicts

John Leppard with Washington Analysis says the Medicare agency’s recent delay of the MCIT breakthrough devices rule until mid-December suggests the CMS will likely scrap it altogether and start from scratch.

CMS Kicks Can Down Road By Pushing MCIT Breakthrough Devices Rule To Dec. 15. Here’s Why

In a move that will undoubtedly ruffle industry feathers, the US Medicare agency on 14 May issued a final rule that moves implementation of the Medicare Coverage of Innovative Technology rule to the end of the year.

37 Lawmakers Urge Acting Medicare Chief To Pull Trigger On MCIT Breakthrough Rule

The US House Democrats signed a letter asking acting CMS administrator Liz Richter to put the Medicare Coverage for Innovative Technology program into place as soon as possible.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel